Browse by author
Lookup NU author(s): Dr Stella Breininger
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2023, The Author(s).Pseudomyxoma peritonei (PMP) is a rare, progressive, slowly growing neoplastic condition which is poorly understood, with a 5-year progression-free survival rate as low as 48%. PMP is most commonly caused by appendiceal mucinous neoplasms (AMN), and understanding their genetic biology and pathogenicity may allow for the development of better novel systemic treatments to target key deleterious mutations and the implicated pathways. The primary aim of this systematic review was to identify the genetic profile of histologically confirmed human PMP or AMN samples. The secondary aim was to identify whether genetic marks could be used to predict patient survival. Ovid EMBASE, Ovid MEDLINE, PubMed, and Web of Science were searched to identify studies investigating the genetic profile of histologically-confirmed human PMP or AMN samples. We review findings of 46 studies totalling 2181 tumour samples. The most frequently identified somatic gene mutations in patients with PMP included KRAS (38–100%), GNAS (17–100%), and TP53 (5–23%); however, there were conflicting results of their effect on survival. Three studies identified molecular subtypes based on gene expression profiles classifying patients into oncogene-enriched, immune-enriched, and mixed molecular subtypes with prognostic value. This review summarises the current literature surrounding genetic aberrations in PMP and AMNs and their potential utility for targeted therapy. Given the recent advances in clinical trials to directly target KRAS and GNAS mutations in other cancers, we propose a rationale to explore these mutations in future pre-clinical studies in PMP with a view for a future clinical trial. Graphical Abstract: [Figure not available: see fulltext.]
Author(s): Murage NW, Ahmed NM, Underwood TJ, Walters ZS, Breininger SP
Publication type: Review
Publication status: Published
Journal: Cancer and Metastasis Reviews
Year: 2023
Volume: 42
Issue: 1
Pages: 335-359
Online publication date: 01/02/2023
Acceptance date: 20/01/2023
ISSN (print): 0167-7659
ISSN (electronic): 1573-7233
Publisher: Springer
URL: https://doi.org/10.1007/s10555-023-10088-0
DOI: 10.1007/s10555-023-10088-0
PubMed id: 36723696
